NASDAQ Global Market • Healthcare • Biotechnology • CA • USD
Sierra Oncology, Inc. (SRRA) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 3 recommend buying, 3 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
